Systemic Lupus Erythematosus (SLE) is an enduring condition that falls under the category of autoimmune diseases. It has the potential to impact nearly every organ in the body, including the skin, joints, kidneys, brain, heart, and lungs. Protheragen offers a comprehensive preclinical drug and therapy development for SLE, advancing solutions to the challenges of SLE, seeking to accelerate breakthroughs in your investigations.
SLE is an archetypal autoimmune disorder that demonstrates a diverse range of clinical features alongside a relapsing-remitting disease course. It is primarily characterized by the loss of immune tolerance that leads to the production of autoantibodies, deposition of immune complexes, and results in inflammation and damage to the organs. It particularly affects women in their reproductive years. It is globally prevalent in the range of 20-70 per 100,000 population. There is an immediate need for therapeutic interventions due to the unpredictable nature of flares, the possibility of severe organ involvement, and the significant unmet need for precise, safer, targeted therapies.
Fig.1 Summary of specific targets of recently approved and investigational SLE therapeutics. (Lazar and Kahlenberg, 2023)Systemic Lupus Erythematosus (SLE) is a condition that stems from genetic factors, environmental influences, and a malfunctioning immune system. It is basically characterized by the breakdown of immune tolerance, which results in the secretion of autoantibodies by activated B cells. These autoantibodies subsequently generate immune complexes that are deposited within tissues, instigating inflammation and damage in organs. The process is mediated by key inflammatory cytokines, Type I interferons, and BAFF.
| Therapeutic Approach | Therapeutic Target/Goal | Development Stage | Key Studies/Evidence | Current Status |
| Optimized Biologics | Volarizumab (Obexelimab) | CD20 inhibition | Enhanced clinical response rates vs monotherapy | Phase III |
| Late-Stage Agents | Telinacicept | BAFF/APRIL dual inhibition | Improved renal response in lupus nephritis trials | Phase III |
| Imsidolimab | IL-36R antagonism | High skin response rates in cutaneous lupus | Phase II | |
| Dapirolizumab | CD40L blockade | Profound B-cell depletion in clinical studies | Phase III | |
| Cenerimod | S1P1 receptor modulation | Reduction in autoantibody titers | Phase III | |
| Baricitinib | JAK1/2 inhibition | Suppression of interferon-driven inflammation in pivotal trials | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen provides a full spectrum of services for therapy advancement in Systemic Lupus Erythematosus (SLE). Our team of scientists, dermatologists, and experienced geneticists employ state-of-the-art technologies and interdisciplinary efforts focused toward facilitating therapeutic development, diagnostics development as well as disease model development services to advance your research project.
In Vivo Pharmacokinetics Services
At Protheragen, we provide comprehensive preclinical therapeutics services toward disease from discovery to development. Our state-of-the-art facilities and experienced team conduct rigorous in vitro and in vivo studies to evaluate the safety and efficacy of potential therapeutics, ensuring that your drug candidates meet the highest standards.
Partner with us to accelerate your Systemic Lupus Erythematosus research and transform therapeutic innovations into effective solutions. If you are interested in our services, please contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
